World Thrombosis Day Steering Committee Members at ISTH 2023

Presentation(s):

• OC 02.4 – Women with severe postpartum hemorrhage have a decreased endogenous thrombin potential before delivery
  Saturday, June 24, 2023
  13:45 – 14:00 ET

• OC 12.3 – Rates of Venous Thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital Hemophilia A or B: a systematic review
  Sunday, June 25, 2023
  11:15 – 11:30 ET

• OC 21.1 – Venous thromboembolism and vascular access thrombosis in patients with end-stage kidney disease on hemodialysis: Prospective results from the VIVALDI study
  Sunday, June 25, 2023
  14:45 – 15:00 ET

• PB0031 – Natural antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events
  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0411 – Platelet glycoprotein IIb- and IIIa levels are altered in persistently lupus anticoagulant positive patients with a history of thrombosis
  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0462 – Early discharge and home treatment of patients with acute pulmonary embolism in the tertiary care setting
  Sunday, June 25, 2023
  18:30 – 19:30 ET

• OC 34.3 – Walking capacity in patients with acute deep vein thrombosis is associated with the location of thrombosis and is reduced in patients with a history of previous deep vein thrombosis
  Monday, June 26, 2023
  11:15 – 11:30 ET

• OC 46.4 – Association of growth differentiation factor-15 (GDF-15) with thromboembolism and mortality in patients with cancer: findings from the Vienna CATS study
  Monday, June 26, 2023
  15:30 – 15:45 ET

• OC 46.5 – Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer
  Monday, June 26, 2023
  15:45 – 16:00 ET

• PB0919 – High rates of bleeding in unselected patients with cancer: results from a prospective cohort study
  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0926 – Venous thromboembolism and risk of depression in patients with hematological cancer: A population-based cohort study
  Monday, June 26, 2023
  18:30 – 19:30 ET

• OC 54.1 – Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of OSCAR Programme Findings
  Tuesday, June 27, 2023
  10:45 – 11:00 ET

• OC 64.2 – Trends in clinical characteristics, treatment and 30-day outcomes in cancer patients with venous thromboembolism from 2001 to 2020
  Tuesday, June 27, 2023
  15:00 – 15:15 ET

• PB1206 – Plasmin generation is impaired in patients with bleeding disorders of unknown cause
  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1277 – Thrombin generation and clot formation and lysis properties in hemophilia A with and without emicizumab
  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1292 – Rationale and Design of pathfinderReal: A Prospective, Non-Interventional Study Assessing Joint Health in Adults With Haemophilia A After Switching to Prophylaxis With Turoctocog Alpha Pegol (N8-GP)
  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1345 – Health-related quality of life assessed by the SF-36 Health Survey in the Vienna ITP Biobank
  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1365 – Serum complement levels in adult patients with primary immune thrombocytopenia
  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1511 – Systematic review on hemostatic biomarkers predictive for postpartum hemorrhage
  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1514 – Pre-delivery thrombin generation in women with non-severe post-partum hemorrhage – a nested case-control study
  Tuesday, June 27, 2023
  18:30 – 19:30 ET